Numerion Labs vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Numerion Labs (fka Atomwise) deploys AtomNet deep learning for ultra-fast virtual drug screening; partnered with Sanofi for up to $1.2B in milestones; rebranded Oct 2025 with new APEX platform for hyper-scalable virtual library screening.
About
Numerion Labs, formerly known as Atomwise, is an AI-driven drug discovery company that uses deep learning to accelerate the identification of small molecule drug candidates. The company''s core technology, AtomNet, is a convolutional neural network trained on vast datasets of protein-ligand interactions to predict binding affinity and drug-likeness at scale. In October 2025, Atomwise rebranded as Numerion Labs, reflecting a sharpened strategic focus on ultra-fast virtual screening and the development of its APEX platform for hyper-scalable chemical library screening — a capability validated in partnership with NVIDIA.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.